Applying the two p53-stratified E2 response signatures, we again observed that the TP53-ER Signature, but not the Non-TP53-ER Signature, differentiated TP53 WT and mutant metastatic tumors (Fig. 3f). This evidence concerns the gene ESR1 and metastatic neoplasm.